Hollis-Eden Pharmaceuticals Announces HE2500 Significantly Reduces Ongoing Paralysis and Accelerates Recovery in Preclinical Model of Multiple Sclerosis.Business Editors/Health & Medical Writers
SAN DIEGO--(BW HealthWire)--April 23, 2002
Data with HE2500 Presented at Experimental Biology Meeting
Hollis-Eden Pharmaceuticals, Inc. (NASDAQ NASDAQ
in full National Association of Securities Dealers Automated Quotations
U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :HEPH) today announced data from a preclinical study demonstrating that HE2500, an investigational immune regulating hormone, significantly reduces ongoing paralysis and accelerates recovery from experimental autoimmune encephalomyelitis Experimental autoimmune encephalomyelitis (EAE) is an animal model of brain inflammation. It is an inflammatory demyelinating disease of the central nervous system (CNS). (EAE EAE
1. experimental allergic encephalomyelitis.
2. enzootic abortion of ewes. ), a preclinical model that mimics multiple sclerosis (MS) in humans.
Dr. Halina Offner, Professor of Neurology at Oregon Health & Science University, conducted the study and is presenting the data at the Federation of American Societies for Experimental Biology The Federation of American Societies for Experimental Biology, or FASEB, is a non-profit federation of 21 societies for biomedical research in the United States. Its mission statement is "to advance biological science through collaborative advocacy for research policies that this week in New Orleans, Louisiana.
[pilcrow (paragraph sign)] The EAE animal model, caused by inflammatory T-cells directed against myelin in the brain and spinal cord, shares many characteristics with MS, and has been widely used to study efficacy in a preclinical model for potential treatments for MS. The experiment was designed to test the effects of HE2500 on the severity of the disease. Treatment of EAE diseased animals with HE2500 injections daily significantly delayed disease onset, reduced the signs of disease, and prevented or attenuated relapses compared to placebo. Also, HE2500 treated animals had a significantly reduced production of inflammatory mediators in the brain. These results suggest that the compound's ability to reduce the severity of the disease was due to its anti-inflammatory action in the brain.
[pilcrow (paragraph sign)] "I am very excited about these initial data, because they demonstrate that this new class of immune regulating hormones is very effective for treating ongoing paralytic paralytic /par·a·lyt·ic/ (par?ah-lit´ik)
1. affected with or pertaining to paralysis.
2. a person affected with paralysis.
1. disease," says Dr. Offner. "HE2500 acts by limiting the entry of inflammatory cells into the brain and thereby reducing the production of inflammatory mediators in the brain. This compound ultimately could be used to treat both men and women with MS and may also be useful to treat other autoimmune diseases. Dose-finding studies are currently being planned for MS."
Preclinical data to support the use of this class of compounds in collagen induced arthritis (CIA CIA: see Central Intelligence Agency.
(1) (Confidentiality Integrity Authentication) The three important concerns with regards to information security. Encryption is used to provide confidentiality (privacy, secrecy). ), an animal model for rheumatoid arthritis, will also be presented by Dr. Offner in May at the 6th International Symposium on the Immunotherapy of Rheumatic Diseases in Limassol, Cyprus.
"The results garnered in this experiment continue to scientifically support the important role immune regulating hormones may play in autoimmune diseases," said Richard Hollis, Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Hollis-Eden Pharmaceuticals. "We are very pleased to be working with Dr. Offner who is a leading researcher in multiple sclerosis and other autoimmune conditions. This result demonstrating the anti-inflammatory properties of HE2500 in this model of MS substantiates the favorable results obtained with HE2500 in an animal model of psoriasis, as well as results demonstrating anti-inflammatory and histological benefits of HE2200 in a model of inflammatory bowel disease inflammatory bowel disease
n. Abbr. IBD
Any of several incurable and debilitating diseases of the gastrointestinal tract characterized by inflammation and obstruction of parts of the intestine. . The previously published clinical results with HE2000 in HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. demonstrated multiple inflammatory chemokines being normalized after therapy. We believe the potential ability to restore and regulate a dysregulated immune system in autoimmune diseases with our drug candidates represents an opportunity to serve a number of important markets. There are significant potential commercial benefits for companies that address these markets with drugs that do not cause immunosuppressive side effects, and can be offered with pharmacoeconomic advantages."
Hollis-Eden Pharmaceuticals, Inc. is a development-stage pharmaceutical company based in San Diego, California “San Diego” redirects here. For other uses, see San Diego (disambiguation).
San Diego is a coastal Southern California city located in the southwestern corner of the continental United States. As of 2006, the city has a population of 1,256,951. , engaged in the development of products for the treatment of infectious diseases and immune systems disorders. The Company's vision is to become the world leader in immune regulating hormones and their application to numerous diseases. HE2000 is the Company's lead investigational drug and is currently being studied in clinical trials for HIV/AIDS in South Africa HIV and AIDS in South Africa are a major health concern, and around 5.5 million people are thought to be living with the virus in South Africa.  HIV (human immunodeficiency virus) is the retrovirus that causes the disease known as AIDS (Acquired Immunodeficiency . Hollis-Eden is also conducting a Phase I/II clinical trial with HE2000 in the United States in HIV infected patients failing at least their second antiviral drug regimen. Phase II studies in Thailand are also being conducted with HE2000 in the treatment of malaria, and in Singapore for the treatment of hepatitis B. In addition, Hollis-Eden recently entered into a Cooperative Research and Development Agreement “CRADA” redirects here. For other uses, see CRADA (disambiguation).
A Cooperative Research and Development Agreement (CRADA) is an agreement between a government agency and a private company to work together. (CRADA) with the United States Department of Defense to develop HE2100 as a radioprotectant (a drug that may potentially be used to protect a person from radiation injury due to a nuclear accident or event). Hollis-Eden recently announced the initiation of a Phase I/II clinical trial with HE2200 for vaccine potentiation potentiation /po·ten·ti·a·tion/ (po-ten?she-a´shun)
1. enhancement of one agent by another so that the combined effect is greater than the sum of the effects of each one alone.
2. posttetanic p. in elderly patients receiving a hepatitis B vaccine hepatitis B vaccine
n. Abbr. HB
A vaccine prepared from the inactivated surface antigen of the hepatitis B virus and used to immunize against hepatitis B. . The Company also has access to HE2500 through its relationship with Aeson Therapeutics. HE2500 is currently being studied in Phase II clinical trials in cardiovascular disease. For more information on Hollis-Eden, contact the Company's website at www.holliseden.com.
Statements made in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to successfully complete clinical trials, the Company's future capital needs, the Company's ability to obtain additional funding and required regulatory approvals, the development of competitive products by other companies, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The actual results may differ materially from those contained in this press release.